The Three Pharmacies That Decide Whether You Get Your Medication

Wednesday's Signal explained the conscience clause — the state law that lets a pharmacist refuse to fill your prescription based on personal belief — and the federal backstop that used to prevent that refusal from becoming a dead end for the patient. The backstop was rescinded in January 2026. Today's Briefing maps what that actually looks like on the ground: which pharmacies, which medications, which states, and what — if anything — can still be done about it.

Three companies, the retail-pharmacy counter.

Let me start with a number that most people do not know.

CVS, Walgreens, and Walmart — the three national retail pharmacy chains remaining after Rite Aid's October 2025 liquidation — collectively account for roughly forty-two percent of all U.S. prescription dispensing revenue, and a materially higher share of the retail-counter channel patients actually walk into.^[9] Rite Aid's roughly six hundred remaining pharmacies were absorbed almost entirely by CVS; Walgreens, Kroger, and Albertsons picked up smaller tranches. The market did not relieve. It concentrated.

That means the dispensing decisions of three corporate boards are, in operational terms, the dispensing decisions of the American retail pharmacy system. When one of those three chains decides not to stock a medication, or adds a twenty-four-hour counseling delay before dispensing it, or tells its pharmacists in certain states that the legal risk is too high — that decision lands on millions of patients simultaneously.

When we talk about pharmacy refusals, we are not talking about a rogue pharmacist here or there. We are talking about corporate policy at three companies that control the last mile of care for most of the country.

Three medications. Three different problems.

There are many medications affected by conscience clauses and chain-level stocking decisions. But three of them tell the whole story.

Misoprostol costs about two dollars. It is the first-line medication for outpatient management of an incomplete miscarriage. It is also used for cervical preparation before procedures, for postpartum hemorrhage, and for induction of labor. It has been on the market for decades. It is on the WHO's List of Essential Medicines.^[3]

In the post-Dobbs environment, the major chains — citing legal-liability concerns — have systematically reduced misoprostol stocking in ban states and imposed pharmacist-review requirements before dispensing.^[2][8] Here is what that means for the patient: she has an incomplete miscarriage. Her doctor prescribes misoprostol. She goes to her local Walgreens, CVS, or Walmart. They do not have it in stock, or the pharmacist flags the prescription for review, or the pharmacist refuses outright.

Mifepristone is the FDA-approved first agent in the medication-abortion regimen. It is also used routinely in managing early pregnancy loss and in treating Cushing's syndrome. In January 2023, the FDA approved pharmacy dispensing of mifepristone — meaning your local pharmacy could stock it and fill a prescription for it, just like any other medication.

The major chains publicly committed to obtaining the certification and stocking it. The operational reality is different. In ban states, the documented pattern is, with limited exceptions, a refusal to certify or stock.^[3] A clinician writing a mifepristone prescription for a non-abortion indication in a ban state in 2026 cannot, in most cases, identify a pharmacy that will fill it.

Meanwhile, twenty-two states plus the District of Columbia have passed shield laws protecting reproductive health providers — and eight of them (California, Colorado, Maine, Massachusetts, New York, Rhode Island, Vermont, and Washington) specifically extend that protection to mail-order mifepristone distribution.^[11] By late 2024, shield-law mail-order was responsible for approximately fourteen thousand medication-abortion procedures per month.^[10] That mail-order infrastructure is the workaround that exists because the retail infrastructure failed. And it is itself under legal threat — but that is a different week's problem.

Emergency contraception — Plan B, ella — is time-sensitive by definition. The entire clinical value of the drug is that you take it quickly. A seventy-five-percent effective regimen at twelve hours becomes substantially less effective at thirty-six hours.

Several chain pharmacies have implemented pharmacist-counseling requirements before dispensing emergency contraception. In operational practice, those requirements produce delays of two to twenty-four hours between the patient presenting with a valid prescription and the patient leaving with the medication.^[2][7] The counseling requirement is framed as a clinical-quality intervention. In practice, in the states where it is applied, it functions as an access-restriction mechanism. The delay is the denial.

The one-pharmacy county.

Here is where the chain-level decisions collide with geography.

In the counties that the March of Dimes classifies as maternity care deserts — 1,104 of them, 35.1% of all U.S. counties — the chain pharmacy closure rate since 2020 has accelerated.^[5] Each closure in a maternity-care-desert county converts the pharmacy access pattern from "drive to the chain in town" to "drive to the next county."

Over fifteen percent of the U.S. population lives in a county with only one retail pharmacy. If that pharmacy's corporate policy restricts misoprostol or mifepristone stocking, or if the pharmacist on duty invokes a conscience clause, the patient has no alternative. She is not inconvenienced. She is embargoed.

There is no federal mechanism to address this. There used to be. There is not anymore.^[1]

What can still be done — three levers.

This is not a situation where nothing can be done. There are three specific mechanisms that exist right now, within the current legal framework, that could restore access. None of them require new federal legislation.

1. State Attorneys General and state Boards of Pharmacy. Pharmacy licensing is a state-level function. The AG and Board of Pharmacy in every protection state — California, New York, Illinois, Washington, Oregon, Massachusetts, Maryland, New Jersey, Colorado, Minnesota, and others — has the authority to require chain pharmacies operating in the state to certify that they will stock and dispense FDA-approved medications consistent with the standard of care. Several have already begun to use it. The most immediately available lever. It does not require new legislation. It requires a state AG who decides to use the authority they already have.
2. FTC antitrust enforcement. The FTC's 2024 Pharmacy Benefit Manager report identified the vertical integration between PBMs and chain pharmacy systems as a competitive harm.^[4] The three chains' market concentration — roughly forty-two percent of all U.S. prescription dispensing revenue and a substantially higher share of the retail-counter channel^[9] — is the structural condition that makes corporate stocking decisions feel like law. The FTC has the authority under Section 5 to challenge that concentration. Antitrust litigation is slow (five to ten years), but it is the lever that addresses the structural problem: that three companies should not have the power to decide which FDA-approved medications are available to the American public.
3. Medicare and Medicaid reimbursement conditions — via CMS rulemaking. This lever is administrative, not legislative. CMS has rulemaking authority over participating-provider standards and could condition federal Medicare and Medicaid pharmacy reimbursement on a chain's certification that FDA-approved medications will be stocked and dispensed consistent with the standard of care.^[6] The lever is the money — Medicare and Medicaid reimbursement is not optional for the chains; it is a significant fraction of their revenue. Adjacent federal legislation has moved in the same neighborhood — PBM Reform was folded into the FY2026 appropriations bill, and the Equitable Community Access to Pharmacist Services Act (ECAPS) has been reintroduced across successive Congresses — but the stocking-condition pathway itself runs through CMS rulemaking, not a new statute.^[12]

The Closer.

Wednesday's Signal told you that the person who never examined you can now refuse your prescription. Today's Briefing is telling you that the decision about whether your medication is available was, in most cases, already made — at a corporate level, by three companies, based on legal exposure rather than clinical need.

The backstop was federal. It is gone. The levers that remain are state-level and structural. They exist. They are available. They have not been pulled.